Prucalopride

Prucalopride is a gastrointestinal prokinetic drug, more precisely a selective, high-affinity agonist of the 5-HT4 subtype of serotonin receptor ^[1][2]. Chemically it is a benzofuran carboxamide with the molecular formula C18H26ClN3O3, and it is taken by mouth as a once-daily tablet ^[1]. A defining feature is its selectivity: it binds 5-HT4 receptors more than a hundredfold more strongly than other receptors, which sets it apart from earlier drugs in its class ^[2].

The compound belongs to a generation of 5-HT4 agonists developed after the withdrawal of older enterokinetic drugs. Cisapride and tegaserod, which also stimulate 5-HT4 receptors, were pulled from many markets because they acted on additional targets in the heart and were linked to serious cardiac rhythm problems ^[2]. Prucalopride was designed to be far more selective for the 5-HT4 receptor, avoiding those off-target actions, and monitoring in its trials found no significant adverse cardiovascular effects ^[1]. It was approved in the European Union in 2009, in Canada in 2011, and in the United States in 2018, and is marketed as Resolor, Resotran, and Motegrity ^[1].

Prucalopride is indicated for chronic constipation, in particular chronic idiopathic constipation that has not responded to laxatives ^[2]. Its effectiveness was established in a series of twelve-week phase 3 trials. In one placebo-controlled study of severe chronic constipation, roughly three in ten patients taking prucalopride reached the target of three or more spontaneous complete bowel movements per week, compared with about one in ten on placebo, alongside improvements in symptom severity and quality of life ^[1]. A second large trial reported similar gains, including in the majority of participants who had been dissatisfied with previous laxatives ^[2]. A 2019 systematic review and network meta-analysis of thirty-three trials in chronic idiopathic constipation ranked prucalopride first among drug therapies at twelve weeks, concluding that it is likely the most effective option for patients who have not responded to laxatives, though long-term comparative evidence remains limited ^[3].

Prucalopride is a prescription-only medicine, supplied as oral tablets taken once daily ^[1]. It is eliminated largely unchanged by the kidneys and has a long half-life that supports its once-daily schedule ^[1]. The most common side effects reported across trials were headache, nausea, abdominal pain, and diarrhoea, which tend to appear early in treatment and then subside ^[1][2].

Common sides are headache, nausea, diarrhea, and abdominal cramping, usually early in treatment. It's a prescription drug and should be used under medical supervision. Older prokinetics had cardiac (QT) concerns; prucalopride is more selective and considered safer, but caution still applies with heart conditions.

Prucalopride was developed by the Belgian company Janssen as a highly selective agonist of the serotonin 5-HT4 receptor, part of a deliberate search for a gut prokinetic that would avoid the cardiac hazards of earlier agents. Its design responded directly to the fate of predecessors such as cisapride and tegaserod, which were effective but were withdrawn or restricted after being linked to serious cardiovascular events attributed to their off-target activity; prucalopride's high receptor selectivity was intended to sidestep those risks.

After clinical development, later carried forward by Shire, it was approved in the European Union in 2009 under the brand name Resolor and by the United States Food and Drug Administration in 2018 as Motegrity, chiefly for chronic idiopathic constipation. Subsequent randomized trials and network meta-analyses have confirmed its efficacy, with one large analysis ranking prucalopride first among drugs at twelve weeks for achieving normal bowel movement frequency in patients who had not responded adequately to laxatives. Its clinical trials showed no significant cardiac signal, supporting the selectivity that motivated its design.

Prucalopride is well regarded as a modern, thoughtfully designed treatment for stubborn chronic constipation, especially for people whose symptoms have resisted ordinary laxatives. Gastroenterologists appreciate that its high selectivity for the 5-HT4 receptor lets it stimulate the natural, coordinated contractions of the colon while avoiding the cardiac problems that ended the careers of older prokinetics.

Its standing is reinforced by strong evidence: a major network meta-analysis ranked it first among all constipation drugs for restoring normal bowel movement frequency at twelve weeks, and a large trial found it comparable to intensive electroacupuncture. It is worth noting that it is generally reserved for second-line use after laxatives, and that it can cause headache, nausea and diarrhea, particularly in the first days. With regulatory approval in both Europe and the United States and a reassuring cardiovascular record, it stands as one of the more trusted advances in the treatment of chronic constipation.